Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Slides:

Advertisements

Similar presentations

Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.

Advertisements

Copyright © 2015 by the American Osteopathic Association.

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

Stuart A. Ross, MB CHB, FRACP, FRCP(C)

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Differences in the glycated hemoglobin (HbA1c) levels.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,

Illustration of the causal inference scheme.

Obesity and type 2 diabetes forecasts.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Calibration plot by quintiles of predicted 5-year diabetes risk of the comprehensive German Diabetes Risk Score (GDRS) for prediction of incident diagnosed.

Adjusted annual percentage of quality indicators by prescription

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Metabolic syndrome—participants with four and five components—expected and observed frequencies by age. Metabolic syndrome—participants with four and five.

Metabolic syndrome—participants with only three components—expected and observed frequencies by age. Metabolic syndrome—participants with only three components—expected.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Results of sensitivity analyses.

Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.

Enrollment of patients.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Glucose-lowering medication in type 2 diabetes: overall approach.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

Comorbid conditions and concomitant medications.

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Linear associations of specific FFAs with inflammatory biomarkers.

Association of body mass index with all-cause mortality in diabetes and non-diabetes populations, by smoking status. Association of body mass index with.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Patient disposition and study protocol.

Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Fitted seasonality for gestational diabetes mellitus (GDM) by estimated date of conception (eDoC). Fitted seasonality for gestational diabetes mellitus.

Indirect effects of factors for diabetes in the STEPwise approach to surveillance 2012 survey—Qatar among adults aged 18–64 years. Indirect effects of.

Presentation transcript:

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders provided by a domain expert (right panel). Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders provided by a domain expert (right panel). Red dots indicate the actual measurements of patients at baseline (before second-line treatment), after 6 and 12 months. Black dots (with error bars) represent the counterfactual predictions and 95% CIs, supposing all patients were treated with that drug class. BMI, body mass index; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1 receptor agonists; SU, sulfonylurea; TZD, thiazolidinedione. Assaf Gottlieb et al. BMJ Open Diab Res Care 2017;5:e000435 ©2017 by American Diabetes Association